louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03419871: Associations of Socioeconomic Adversity and Sleep With Allostatic Load Among Toddlers
Official title: Sleep, Biological Stress, and Health Among Toddlers Living in Socioeconomically Disadvantaged Homes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Disorder
Keywords: economically stressed communities
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2018-02-05
Enrollment: 100
Sex: ALL
Minimum age (years): 12
Maximum age (years): 15
Standard ages: CHILD
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Toddlers (12-24 months- ages 12-15 months at enrollment) living in socioeconomically disadvantaged homes.

Brief summary: A longitudinal study to examine the relationships among sleep characteristics, stress, and child behavior problems in a community sample of toddlers (12-24 months- ages 12-15 months at enrollment) living in socioeconomically disadvantaged homes

Detailed description: The purpose of this study is to examine the relationships among sleep characteristics, stress (allostatic load), and health among toddlers living in economically stressed communities. Sleep difficulty, including short sleep duration and poor sleep efficiency, is closely related to measures of stress, including interleukin (IL-6), cortisol, c-reactive proteins (CRP), secretory immunoglobulin A (SIgA), and body mass index (BMI) and may therefore contribute to 'wear and tear' on the body (allostatic load), a problem that places children at high risk of physical and mental health problems. Young children who live with socioeconomic adversity are especially vulnerable to both sleep difficulty and higher levels of physiologic stress (allostatic load).

Eligibility criteria: Inclusion Criteria:

* Toddlers (12-24 months- ages 12-15 months at enrollment) living in socioeconomically disadvantaged homes.

Exclusion Criteria:

* If the toddler has a diagnosis of sleep apnea or has another documented medical condition affecting sleep.

Primary outcomes:
measure: Sleep monitoring
timeFrame: 9 days
measure: Caregiver report
timeFrame: 12 to 36 months
measure: Sleep diary
timeFrame: 12 to 24 months
measure: Behavioral monitoring
timeFrame: 12 to 36 months
Secondary outcomes:
measure: Cortisol biomarker
timeFrame: 12 to 24 months
measure: Immune biomarkers
timeFrame: 12 to 24 months
measure: Anthropometric biomarkers
timeFrame: 12 to 24 months
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale New Haven Hospital Primary Care Center
state: Connecticut
Study officials:
affiliation: Yale University School of Nursing
name: Monica Ordway, Phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00299871: Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
Official title: A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Type 2 Diabetes
Keywords: Type 2 diabetes
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2006-03-07
Enrollment: 542
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the dose-response relationship of AVE0010 administered once daily and twice daily with chronic dosing in metformin-treated subjects with type 2 diabetes


Eligibility criteria: Inclusion Criteria:

* Males, females, age 30, - 75 years, type 2 diabetes mellitus, treated with metformin ≥1.0 g/day, at a stable dose for at least 3 months, BMI 25 - 40 kg/m2, HbA1C ≥7.0% and \<9.0%.

Exclusion Criteria:

* Type 1 diabetes, pregnancy, lactation, women of childbearing potential, treatment with other antidiabetic agents than metformin, history of metabolic acidosis, hemoglobinopathy or hemolytic anemia, clinically significant medical abnormalities.

Primary outcomes:
measure: HbA1c levels at baseline and endpoint (at 13 weeks).
Secondary outcomes:
measure: Fructosamine, fasting plasma glucose, fasting serum insulin, proinsulin, C-peptide, glucagon.
Other outcomes:
Locations:
city: Bridgewater
country: United States
facility: Sanofi-Aventis Administrative Office
state: New Jersey
city: Sao Paulo
country: Brazil
facility: Sanofi-Aventis Administrative Office
city: Laval
country: Canada
facility: Sanofi-Aventis Administrative Office
city: Warszawa
country: Poland
facility: Sanofi-Aventis Administrative Office
city: Bucuresti
country: Romania
facility: Sanofi-Aventis Administrative Office
city: Moscow
country: Russian Federation
facility: Sanofi-Aventis Administrative Office
city: Kiev
country: Ukraine
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: ICD CSD
role: STUDY_DIRECTOR
References:
citation: Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010 Sep;27(9):1024-32. doi: 10.1111/j.1464-5491.2010.03020.x.
Clinical trial NCT00189371: Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
Official title: Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Platinum Sensitve Relapse
Anemia
Lead sponsor: AGO Study Group
Sponsor class: OTHER
First posted: 2005-09-19
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but about 70% will eventually relapse. Relapse more than 6 months following first line chemotherapy is regarded as platinum/taxane sensitive disease. Reinduction chemotherapy with platinum/taxane is known to be an effective treatment option. Therapy induced anemia is a common problem resulting in decrease of quality of life. The rationale of this trail is to evaluate the effects of epoetin alpha on reduction of therapy induced anemia, rate of transfusions and on quality of life.


Eligibility criteria: Inclusion Criteria:

* Relapse longer than 6 months after termination of platinum/taxane based first line chemotherapy
* Previously histologically confirmed cancer of: ovary, fallopian tube, peritoneum
* measurable and evaluable lesions by ultrasound, computer-tomography or MRI
* Performance status ECOG \< 2 or karnofsky index \> 60%
* normal organ function

Exclusion Criteria:

* more than 1 chemotherapy prior enrollment
* ongoing treatment with epoetin alpha or related drugs
* history of thrombosis or embolism during the past 12 months prior enrollment
* ileus
* left ventricular failure \> NYHA classification \> 2
* Ongoing toxicity of any kind (\> CTC Grad II)

Primary outcomes:
measure: Reduction of anemia
Secondary outcomes:
measure: Quality of life
measure: Overall survival
measure: Progression free survival
measure: Toxicity
Other outcomes:
Locations:
city: Marburg
country: Germany
facility: Department of Gynecology University of Marburg
Study officials:
affiliation: AGO Study Group
name: Christian Jackisch, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01991171: Effectiveness of the Kinesio Taping® in Muscle Activation
Official title: Effectiveness of the Kinesio Taping® in Activation of Quadriceps Muscle and Reflex Inhibition of Hamstrings Muscle: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Muscle Atrophy
Keywords: kinesio taping
Muscle activation
Muscle inhibition
Lead sponsor: Paulista University
Sponsor class: OTHER
First posted: 2013-11-25
Enrollment: 48
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Forty-eight female patients will be randomized into three groups to receive the Kinesio taping, placebo Kinesio taping and control group. The group Kinesio taping receive the correct application of the method described. The placebo group will receive a placement without tension. The control group did not receive any form of intervention.

Detailed description: The group Kinesio taping receive the correct application of the method described with tension of 40%. The placebo group will receive a placement without tension.

The control group did not receive any form of intervention.

Eligibility criteria: Inclusion Criteria:

* Woman
* Sedentary

Exclusion Criteria:

* Physically active,
* pain
* men
* musculoskeletal injury in the last six months.

Primary outcomes:
measure: Vertical Jump
timeFrame: 40 minutes
Secondary outcomes:
measure: Flexibility
timeFrame: 40 minutes
Other outcomes:
Locations:
city: Jundiaí
country: Brazil
facility: Universidade Paulista
state: São Paulo
Study officials:
affiliation: Paulista University
name: Mauricio Luz, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05303571: Project Bidof - Monovision by Pairing Bifocal and EDOF Lens
Official title: Project Bidof - Achieving Hybrid Monovision by Pairing Bifocal and EDOF Lens Technology
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Cataract Senile
Lead sponsor: Johannes Kepler University of Linz
Sponsor class: OTHER
First posted: 2022-03-31
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient between 21 and 99 years after cataract surgery

Brief summary: Modern day cataract surgery isn't just a rehabilitative procedure anymore but rather aims at improving a patient's quality of life by reducing the need for spectacles in everyday life to a minimum. One way of achieving this goal is by using different lens technologies, such as a mono- or bifocal lens paired a lens with EDOF technology, as EDOF lenses provide an enhanced depth of focus by creating a single elongated focal point. As this method is well established, the aim of this study is to compare the monofocal/EDOF cohort to the bifocal/EDOF cohort and evaluate visual acuity and patient satisfaction for both combinations.


Eligibility criteria: Inclusion Criteria:

* Age between 21 and 99 years
* signed informed consent form
* condition after cataract surgery

Exclusion Criteria:

* no signed informed consent form
* laser treatment of the Cornea
* macular pathologies
* corneal pathologies
* irregular astigmatism
* pregnancy

Primary outcomes:
measure: Distance Visual Acuity
timeFrame: 6 months
measure: Intermediate Visual Acuity
timeFrame: 6 months
measure: Near Visual Acuity
timeFrame: 6 months
Secondary outcomes:
measure: contrast vision
timeFrame: 3 months
measure: Halo and Glare
timeFrame: 3 months
measure: Defocus curve
timeFrame: 3 and 6 months
Other outcomes:
Locations:
city: Linz
country: Austria
facility: Johannes Kepler University
state: Upper Austria
Study officials:
References:
Clinical trial NCT00380471: Treatment and Complication of Bath PUVA in Vitiligo
Official title: Treatment and Complication of Bath PUVA in Vitiligo
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Vitiligo
Keywords: bath PUVA
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2006-09-26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether bath PUVA are effective in treatment of vitiligo and what is the complication of bath PUVA in vitiligo.


Eligibility criteria: Inclusion Criteria:

* Vitiligo

Exclusion Criteria:

* Pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Skin Research Center, Shaheed Beheshti Medical University
Study officials:
affiliation: Shahid Beheshti University of Medical Sciences
name: Parviz Toossi, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT06171971: Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers
Official title: Evaluation of the Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pediatric Solid Tumors
Keywords: Pediatric solid tumors
BROAD GENOMIC STUDIES
SOLID CANCERS
Genomic medicine
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-12-15
Enrollment: 230
Sex: ALL
Minimum age (years): 1
Maximum age (years): 22
Standard ages: CHILD
ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients of pediatric age up to 22 years included at the time of molecular analysis

Brief summary: Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survival of \< 30%. Progress has been made in genomic medicine with existing recommendations for the adult population, with the objective of personalized medicine. Recommendations for the pediatric population are still under consideration


Eligibility criteria: Inclusion criteria

* Patients of pediatric age up to 22 years included at the time of molecular analysis
* Histological carcinological diagnosis performed at HUS
* Carcinological follow-up performed at HUS
* Patients with a solid tumor of unfavorable prognosis, refractory or in relapse
* Molecular analysis performed on tumor or blood samples
* Adult patients who do not object to the re-use of their personal data for medical research purposes
* Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes.

Criteria for non-inclusion

* Molecular biology results not usable due to poor sample quality or insufficient genetic material
* Patients who have expressed their opposition to participate in the study
* Parental authority holders who have expressed their opposition to participate in the study

Primary outcomes:
measure: Retrospective description of the clinical and therapeutic impact of the systematic performance of molecular analyzes on solid tumors
timeFrame: up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service d'onco-hématologie pédiatrique - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT05770271: The Novel Electrolyzed Water Spray Treatment Mild Senile Groin Eczema, Neurodermatitis and Psoriasis
Official title: A Novel Electrolyzed Water Spray Reduces the Itching Scores of Patients With Mild Senile Groin Eczema, Neurodermatitis and Psoriasis: A Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Groin Infection
Neurodermatitis
Psoriasis
Eczema
Keywords: Electrolyzed water device
Hydroxyl radical
Tap water
Spray
Itching
Lead sponsor: Dove Medical Press Ltd
Sponsor class: NETWORK
First posted: 2023-03-15
Enrollment: 21
Sex: ALL
Minimum age (years): 35
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test whether spraying the itching of inflammation skin and groin patients by use of the novel electrolyzed water spray will produce improvement in the condition of itching.

Detailed description: In this study, water inculding tap water,pure water and salt water, and an apparatus for producing electrolyzed water (https://www.deposon.com.cn; https://www.deposon.com）were used to generate an electrolyzed water mist spray or spray. This instantly generated electrolyzed water mist spray or spray has oxidation-reduction potential (ORP) ≥1200mv,and contains non-specific total oxidation capacity which equals to 0.28±0.10ppm,0.06±0.04ppm and 3.92±0.39ppm of desolved ozone. This instantly generated electrolyzed water mist spray or spray does not release detectable ≥0.1mg/m3 of gaseous ozone. This instantly generated electrolyzed water mist spray or spray has pH 8.4±0.4 and releases negative air ion.The apparatus for producing electrolyzed water has a positive electrode which is covered by a conductive diamond material (Patent# CN215308550U). This is an open-label, single-arm, and before and after treatment comparison study. This study uses this novel electrolyzed water device and the water spray to treat mild senile groin eczema, neurodermatitis and psoriasis.

Eligibility criteria: Inclusion Criteria:

* mild senile groin eczema, neurodermatitis and psoriasis.

Exclusion Criteria:

* severe senile groin eczema, neurodermatitis and psoriasis.
* people with cognitive disorders.
* 80 years or older.

Primary outcomes:
measure: An itching scale made by modifying the Numeric Pain Rating Scale (NPRS)
timeFrame: 1 hour
Secondary outcomes:
measure: A skin signs scale made by modifying the Numeric Pain Rating Scale (NPRS).
timeFrame: 10 days
Other outcomes:
Locations:
city: Qingdao
country: China
facility: Huinuode Biotechnology Co., Ltd.
Study officials:
References:
Clinical trial NCT01126671: Vitamin D Supplementation in Healthy Adolescents
Official title: Clinical Trial of Vitamin D Supplementation in Healthy Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vitamin D Supplementation
Keywords: vitamin D
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
First posted: 2010-05-20
Enrollment: 56
Sex: ALL
Minimum age (years): 11
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This double blind, randomized controlled trial compares two supplemental doses of vitamin D in health adolescents.

Detailed description: Vitamin D deficiency is a common problem. Currently, data do not support a recommended vitamin D supplementation dose for health adolescents to maintain normal vitamin D levels. This double blind, randomized controlled 12 week trial compares the use of two supplemental doses of vitamin D in this population.

Eligibility criteria: Inclusion Criteria:

* 11-18 years old
* healthy

Exclusion Criteria:

* chronic disease
* use of medication known to effect bone or vitamin D metabolism
* abnormal vitamin D or calcium at screening
* pregnant
* body mass index \<5% or \>95%

Primary outcomes:
measure: Baseline 25 Hydroxy Vitamin D (25OHD) Levels
timeFrame: Baseline
measure: Follow-up 25OHD Levels
timeFrame: 12 weeks
Secondary outcomes:
measure: Baseline Assessment of Bone Markers
timeFrame: Baseline
measure: Assessment of Bone Markers at Follow-up
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Boston
country: United States
facility: Children's Hospital Boston
state: Massachusetts
Study officials:
affiliation: Childrens Hospital, Boston
name: Melissa Putman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Childrens Hospital, Boston
name: Sarah Pitts, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Putman MS, Pitts SA, Milliren CE, Feldman HA, Reinold K, Gordon CM. A randomized clinical trial of vitamin D supplementation in healthy adolescents. J Adolesc Health. 2013 May;52(5):592-8. doi: 10.1016/j.jadohealth.2012.10.270. Epub 2012 Dec 23.
Clinical trial NCT05108571: Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fasting State
Official title: An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of DA-5210 10/1000mg in Healthy Subjects at Fasting State
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Dong-A ST Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-11-05
Enrollment: 40
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Phamacokinetics and safety profiles of DA-5210 10/1000mg in Healthy subjects at Fasting State


Eligibility criteria: Inclusion Criteria:

* Healthy Volunteers
* BMI between 18 and 30 kg/m2
* Body weight : Male≥50kg, Female≥45kg

Exclusion Criteria:

* Allergy or Drug hypersensitivity
* Clinically significant Medical History

Primary outcomes:
measure: AUCt
timeFrame: pre-dose~48 hours post-dose
measure: Cmax
timeFrame: pre-dose~48 hours post-dose
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: H Plus Yangji Hospital
Study officials:
References:
Clinical trial NCT03324971: Medication Regimen Complexity and Glycemic Control in Patients With Diabetes
Official title: Effect of Reducing Medication Regimen Complexity on Glycemic Control in Patients With Diabetes.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2017-10-30
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A prospective cohort study .The aim of this study to recruit a cohort of diabetic patients,eliminate unnecessary medications,aiming at improving adherence to anti-diabetic medications.
Primary purpose: TREATMENT

Brief summary: Polypharmacy is an alarming health issue that is defined as prescription of multiple medications, of which some are redundant or unnecessary. Due to comorbidities, diabetic patients are often prescribed multiple medications. Over prescribing occurs either due to, prescribing medications that are not indicated, continuation of certain medications beyond the time of indication, or prescribing more than one medication with the same effect. Improving glycaemic control is the cornerstone for the prevention and treatment of the diabetic complications.

Detailed description: Hypothesis In addition to the side effects and cost of the unnecessary medications, the investigators hypothesis is that poly-pharmacy will adversely affect patients' compliance with the necessary medications.The investigators propose that elimination of unnecessary medications might improve patients' compliance and consequently improve glycemic control diabetic patients.

Eligibility criteria: Inclusion Criteria:

All diabetic patients who are eligible by fulfilling all of the following criteria:

1. HGBA1c ≥7 mg/dl.
2. 2) Poly-pharmacy: defined as the use of five or more medications.
3. Non- compliance: patients were surveyed with both direct and indirect methods to identify non adherence.

Exclusion Criteria:

Exclusion after recruitment Any patient whose diabetic medications regimen changed after recruitment due to hospitalisation, illness, stress or patients preference, will be excluded.

Primary outcomes:
measure: Change in Hemoglobin A1c
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo university hospitals
Study officials:
affiliation: Cairo University Hospitals
name: Tarek S Abdealziz
role: PRINCIPAL_INVESTIGATOR
References: